Results 181 to 190 of about 48,812 (228)

Contemporary Multimodal Management of Cutaneous Malignancies: Surgery, Radiotherapy, Systemic Therapy, Molecular Targeting and Immunotherapy. [PDF]

Cancers (Basel)
Kowalczyk D, Jaworek J, Ciborek A, Kolodziejski PA, Pruszyńska-Oszmałek E, Krauss H.   +5 more
europepmc   +1 more source

Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma. [PDF]

Hepat Oncol
Syed A, Akce M, Malla M.
europepmc   +1 more source

Ocular adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database. [PDF]

Front Pharmacol
Liu X, Ji A.
europepmc   +1 more source

Immunotherapy in Bellini Duct Carcinoma: A Systematic Review. [PDF]

Oncol Res
Lázaro-Sánchez AD, Benítez-Fuentes JD, Wikström-Fernández S, Nevado-Rodríguez M, Conesa-Zamora P, Luengo-Gil G, Ivars-Rubio A, Zafra-Poves M, Carosella ED, Fernández-Molina B, Nieto-Olivares A, Sánchez de Las Matas Garre MJ, Arroyo AB.   +12 more
europepmc   +1 more source

Phase 1/2 study of INCAGN01876, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, plus immunotherapy for advanced cancers. [PDF]

Oncologist
Hamid O, Forget F, Johnson M, George TJ, Bourayou N, Ioannidis S, Zhou F, Yang H, Dong Z, Gutierrez ME.   +9 more
europepmc   +1 more source

Acquired Autoimmune Factor XIII Deficiency as a Novel Immune-Related Adverse Event of Combined Ipilimumab and Nivolumab Therapy for Renal Cell Carcinoma: A Case Report. [PDF]

IJU Case Rep
Tetsushi S, Mikifumi K, Satoshi O, Shuji H, Katsunori T.   +4 more
europepmc   +1 more source

Encapsulated cell therapy for local anti-CTLA-4 delivery in cancer immunotherapy. [PDF]

iScience
Engel A, Vernet R, Charrier E, Urwyler M, Von Rohr O, Saingier V, Courtout F, Abukscem S, Bouvarel T, Lathuiliere A, Guillarme D, Mach N, Grogg J.   +12 more
europepmc   +1 more source